(UL) Unilever - Overview
Sector: Consumer Defensive | Industry: Household & Personal Products | Exchange: NYSE (USA) | Market Cap: 122.525m USD | Total Return: -15.9% in 12m
Personal Care, Foods, Home Care, Beauty Products
Total Rating 50
Safety 85
Buy Signal -0.73
Household & Personal Products
Industry Rotation: +7.4
Industry Rotation: +7.4
Market Cap:
123B
Avg Turnover: 233M
Avg Turnover: 233M
Risk 3d forecast
Volatility26.1%
VaR 5th Pctl4.30%
VaR vs Median-0.18%
Reward TTM
Sharpe Ratio-0.93
Rel. Str. IBD13.1
Rel. Str. Peer Group34.2
Character TTM
Beta-0.010
Beta Downside-0.087
Hurst Exponent0.559
Drawdowns 3y
Max DD25.09%
CAGR/Max DD0.10
CAGR/Mean DD0.35
Warnings
Choppy Below Avwap Earnings
Tailwinds
No distinct edge detected
Description: UL Unilever
Unilever PLC is a London-based multinational corporation specializing in fast-moving consumer goods (FMCG). The company manages a diverse portfolio across four primary segments: Beauty & Wellbeing, Personal Care, Home Care, and Foods. Its brand stable includes globally recognized names such as Dove, Knorr, Hellmann’s, and Rexona, serving markets across the Americas, Europe, Asia Pacific, and Africa.
The FMCG sector is characterized by high volume, low-margin products that require extensive distribution networks and significant marketing investment to maintain market share. Unilever utilizes a multi-channel business model, selling through traditional retail, e-commerce, and professional food services to mitigate regional economic volatility. For a deeper analysis of these market dynamics, you may wish to explore the data on ValueRay.
Founded in 1860, the company has expanded its reach into high-growth categories like Prestige Beauty and Health & Wellbeing. This strategic diversification allows the firm to balance stable revenue from household staples with the higher margins typically found in premium skincare and nutritional supplements.
- Rising input costs and commodity inflation pressure underlying operating margins
- Strategic divestment of ice cream unit streamlines portfolio for higher growth
- Emerging market volume growth offsets sluggish consumer demand in European markets
- Prestige beauty and health segments drive premiumization and revenue expansion
- Brand marketing reinvestment levels determine long-term market share retention rates
Piotroski VR‑10 (Strict)
8.0
| Net Income: 11.82b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.21 > 0.02 and ΔFCF/TA 5.18 > 1.0 |
| NWC/Revenue: -4.13% < 20% (prev -6.27%; Δ 2.14% < -1%) |
| CFO/TA 0.26 > 3% & CFO 18.04b > Net Income 11.82b |
| Net Debt (25.65b) to EBITDA (24.12b): 1.06 < 3 |
| Current Ratio: 0.79 > 1.5 & < 3 |
| Outstanding Shares: last quarter (2.20b) vs 12m ago -13.16% < -2% |
| Gross Margin: 69.99% > 18% (prev 0.25%; Δ 6.97k% > 0.5%) |
| Asset Turnover: 152.8% > 50% (prev 118.9%; Δ 33.91% > 0%) |
| Interest Coverage Ratio: 14.04 > 6 (EBITDA TTM 24.12b / Interest Expense TTM 1.50b) |
Altman Z''
2.99
| A: -0.07 (Total Current Assets 17.06b - Total Current Liabilities 21.65b) / Total Assets 70.44b |
| B: 0.63 (Retained Earnings 44.21b / Total Assets 70.44b) |
| C: 0.29 (EBIT TTM 21.10b / Avg Total Assets 72.83b) |
| D: -0.55 (Book Value of Equity -29.04b / Total Liabilities 52.86b) |
| Altman-Z'' Score: 2.99 = A |
Beneish M
-3.32
| DSRI: 1.25 (Receivables 7.67b/4.94b, Revenue 111.26b/89.41b) |
| GMI: 0.35 (GM 69.99% / 24.55%) |
| AQI: 1.02 (AQ_t 0.63 / AQ_t-1 0.62) |
| SGI: 1.24 (Revenue 111.26b / 89.41b) |
| TATA: -0.09 (NI 11.82b - CFO 18.04b) / TA 70.44b) |
| Beneish M-Score: -3.32 (Cap -4..+1) = AA |
What is the price of UL shares?
As of May 20, 2026, the stock is trading at USD 57.22 with a total of 3,248,921 shares traded.
Over the past week, the price has changed by -0.26%, over one month by -0.33%, over three months by -19.16% and over the past year by -15.87%.
Over the past week, the price has changed by -0.26%, over one month by -0.33%, over three months by -19.16% and over the past year by -15.87%.
Is UL a buy, sell or hold?
Unilever has received a consensus analysts rating of 4.00.
Therefore, it is recommended to buy UL.
- StrongBuy: 2
- Buy: 0
- Hold: 2
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the UL price?
| Analysts Target Price | 68.1 | 19% |
Unilever (UL) - Fundamental Data Overview
as of 17 May 2026
Market Cap EUR = 105.07b (122.53b USD * 0.8575 USD.EUR)P/E Trailing = 18.5
P/E Forward = 15.9744
P/S = 2.4261
P/B = 6.9815
P/EG = 10.6573
Revenue TTM = 111.26b EUR
EBIT TTM = 21.10b EUR
EBITDA TTM = 24.12b EUR
Long Term Debt = 25.70b EUR (from longTermDebt, last quarter)
Short Term Debt = 2.58b EUR (from shortTermDebt, last quarter)
Debt = 29.59b EUR (from shortLongTermDebtTotal, last quarter)
Net Debt = 25.65b EUR (from netDebt column, last quarter)
Enterprise Value = 130.72b EUR (105.07b + Debt 29.59b - CCE 3.94b)
Interest Coverage Ratio = 14.04 (Ebit TTM 21.10b / Interest Expense TTM 1.50b)
EV/FCF = 8.81x (Enterprise Value 130.72b / FCF TTM 14.84b)
FCF Yield = 11.36% (FCF TTM 14.84b / Enterprise Value 130.72b)
FCF Margin = 13.34% (FCF TTM 14.84b / Revenue TTM 111.26b)
Net Margin = 10.62% (Net Income TTM 11.82b / Revenue TTM 111.26b)
Gross Margin = 69.99% ((Revenue TTM 111.26b - Cost of Revenue TTM 33.39b) / Revenue TTM)
Gross Margin QoQ = none% (prev none%)
Tobins Q-Ratio = 1.86 (Enterprise Value 130.72b / Total Assets 70.44b)
Interest Expense / Debt = 1.57% (Interest Expense 464.5m / Debt 29.59b)
Taxrate = 33.31% (1.20b / 3.60b)
NOPAT = 14.07b (EBIT 21.10b * (1 - 33.31%))
Current Ratio = 0.79 (Total Current Assets 17.06b / Total Current Liabilities 21.65b)
Debt / Equity = 1.91 (Debt 29.59b / totalStockholderEquity, last quarter 15.52b)
Debt / EBITDA = 1.06 (Net Debt 25.65b / EBITDA 24.12b)
Debt / FCF = 1.73 (Net Debt 25.65b / FCF TTM 14.84b)
Total Stockholder Equity = 18.40b (last 4 quarters mean from totalStockholderEquity)
RoA = 16.23% (Net Income 11.82b / Total Assets 70.44b)
RoE = 64.23% (Net Income TTM 11.82b / Total Stockholder Equity 18.40b)
RoCE = 47.85% (EBIT 21.10b / Capital Employed (Equity 18.40b + L.T.Debt 25.70b))
RoIC = 43.62% (NOPAT 14.07b / Invested Capital 32.27b)
WACC = 4.87% (E(105.07b)/V(134.66b) * Re(5.95%) + D(29.59b)/V(134.66b) * Rd(1.57%) * (1-Tc(0.33)))
Discount Rate = 5.95% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.92%
Shares (yearly) Correlation: -100.0 | Cagr: -1.32%
[DCF] Terminal Value 88.44% ; FCFF base≈13.69b ; Y1≈16.89b ; Y5≈28.81b
[DCF] Fair Price = 371.9 (EV 835.82b - Net Debt 25.65b = Equity 810.17b / Shares 2.18b; r=6.0% [WACC]; 5y FCF grow 25.0% → 3.0% )
EPS Correlation: -11.90 | EPS CAGR: -61.30% | SUE: 0.0 | # QB: 0
Revenue Correlation: 6.50 | Revenue CAGR: -7.55% | SUE: N/A | # QB: 0
EPS current Year (2026-12-31): EPS=3.17 | Chg30d=-0.38% | Revisions=-14% | GrowthEPS=+2.8% | GrowthRev=+1.7%
EPS next Year (2027-12-31): EPS=3.35 | Chg30d=-0.18% | Revisions=-33% | GrowthEPS=+6.0% | GrowthRev=+3.8%
[Analyst] Revisions Ratio: -33%